PR87687

NANCHANG, China, Jan. 20, 2021 /Xinhua=KYODO JBN/--

On January 15, Jemincare Group, a Chinese pharmaceutical company, announced that it

has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody (JMB2002).

Preclinical studies of JMB2002 including pharmacology and toxicity were carried

out systemically. The drug metabolism, safety and efficacy were well performed.

In early studies, it was found that JMB2002 could effectively neutralize live

virus infection of Vero E6 cells. What's more, JMB2002 showed potent binding

and blocking activities to the spike glycoproteins of mutant viruses.

While most of the SARS-CoV-2 neutralizing antibodies in clinical trial are

produced from cell pool, the product for clinical trial of JMB2002 is produced

from high yield stable cell line, that ensure the consistency and stability of

clinical samples. JMB2002 is derived from naive human B cell antibody library

of healthy donors. With the powerful phage-to-yeast platform, researchers quickly

pinpoint the ideal candidates from over 10 billion antibody molecules in 19 days.

As one of the large-scale and modernized pharmaceutical groups in China,

Jemincare Group, making breakthrough achievements in recent 2 years, has

focused on the R&D of new drugs over the years with R&D pipeline for treating

diseases in cancer, central nervous system, respiratory system, cardiovascular

and cerebrovascular systems. In 2018, Jemincare established its Research

Institute in Shanghai Zhangjiang Science City and has recruited over 400 R&D

scientists in 5 research centers for development of innovative drugs including

biologics, novel small molecules, novel drug delivery system, generic drugs and

traditional Chinese medicines.

For more information, please visit

http://www.jemincare.com/ ,

https://mp.weixin.qq.com/s/ctxPE6bA2CIvfknZoRwwKg

Source: Jemincare